Copenhagen, Denmark, 28 July 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the dosing of the first patient in its Phase 2a trial evaluating AT7687, the Company’s first-in-class Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist, in combination with semaglutide for the treatment of people with obesity and type 2 diabetes.